Navigation Links
Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Date:8/19/2007

NEW YORK, Aug. 9 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and inflammatory diseases, announced today the addition of two sites to its Phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine carcinoma (advanced carcinoid cancer). With the addition of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 676 N. St. Clair Street, Suite 850, Chicago, IL and the H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, the Phase II clinical trial is presently being conducted in seven sites. The principal investigator for Northwestern is Mary Mulcahy, MD, and the principal investigator for Lee Moffitt is Larry K. Kvols, M.D.

"The addition of these two major cancer centers to the Phase II trial of Atiprimod in advanced carcinoid patients signifies our continuing commitment to facilitate rapid enrollment of this trial," said Dr. Gary S. Jacob, Chief Executive Officer of Callisto. "Both sites are active in the treatment of neuroendocrine cancers, and have built significant reputations within the carcinoid community, which should substantially enhance the pace of enrollment and increased accessibility to prospective patients interested in participating in this trial." Currently Callisto has enrolled 31 patients of the 40 subjects planned for this Phase II clinical trial.

The primary objective of the Phase II clinical trial is to evaluate efficacy of Atiprimod in patients with low to intermediate grade neuroendocrine carcinoma who have metastatic or unresectable cancer and who have progression of their disease despite standard therapy (octreotide). Patients, after signing an informed consent, are required to complete two weeks of a symptoms diary to establish their symptoms baseline before commencing Atiprimod dosing. A maximum of 40 evaluable patients will be enrolled in th
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2008)... products highlight Watson,s commitment to urology...T, ORLANDO, Fla., May 21 /...ading specialty pharmaceutical company, announced,...n two Phase 3 products at,the American Urological ...e,a cardiac safety trial involving silodosin, an i...
(Date:5/21/2008)...N.J., May 21 /- Genta,Incor...multiple abstracts,featuring its lead oncology pro...of the American Society of Clinical Oncology (ASCO...acts include the following:, -- Initial Phase 1 ...an oral gallium-containing Compound. Poster #...
(Date:5/21/2008)...t American Urological Association Annual Meeting -...irstCall/ -- Researchers,from Dendreon Corporation...,demonstrating the potential of D-3263, Dendreon,s... Trp-p8 (a transmembrane cation channel protein al...erplasia (BPH)., The abstract (#2041), "Preclinic...
(Date:5/20/2008)...echnologies received positive results of nine mont...and Supralimus. The results unveiled during ..., India, May 20 /- Sahajanand Medical...ng developer and manufacturer of,drug-eluting sten...ve,randomized nine months results of PAINT trial ...
Breaking Medicine Technology:Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 2Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 3Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 4Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 5Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 6Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology 2Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology 3Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia 2Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia 3Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia 4Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents 2Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents 3Full Year 2007 Results Date Notification 21 February 2008 3232 1Full Year 2007 Results Date Notification 21 February 2008 3232 2Surgery improves quality of life for children with sleep apnea 11679 1Surgery improves quality of life for children with sleep apnea 11679 2Surgery improves quality of life for children with sleep apnea 11679 3Old dogs 3A Prior knowledge affects how consumers accept new information 11676 1Old dogs 3A Prior knowledge affects how consumers accept new information 11676 2National Lt Governors Association Endorses HERO Campaign 3B 1st National Association of State Elected Officials Supporting Grassroots Designated Driv 11673 1National Lt Governors Association Endorses HERO Campaign 3B 1st National Association of State Elected Officials Supporting Grassroots Designated Driv 11673 2
... results report no new stent thrombosis after two ...s., and BARCELONA, Spain, May 22, 2007,/PRNewswire...,announced four-year follow-up data from its TAXUS... safety and efficacy benefits,associated with a mo...(TM) paclitaxel-eluting stent system -- which is n...
...LONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Profe...lbourne, Australia, on,Tuesday presented positive ...nical trial at the EuroPCR meeting in Barcelona, S...rdiac events and no,protocol-defined stent thrombo...avor(R) Resolute drug-eluting stent system with ne...
Other Medicine Technology:Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 2Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 3Medtronic Announces Positive Nine-Month Results for Endeavor,Resolute Next Generation Drug-Eluting Stent at EuroPCR 2Medtronic Announces Positive Nine-Month Results for Endeavor,Resolute Next Generation Drug-Eluting Stent at EuroPCR 3
(Date:5/21/2008)...y 21 /PRNewswire-FirstCall/ -- Aflac Incorporated,...presentation at the Sanford,C. Bernstein & Co., LL...nce,2008., President and Chief Financial Officer ...ted, and he is scheduled to make a presentation on...orated presentation, Mr.,Cloninger will discuss th...
(Date:5/21/2008)...d SILVER SPRING, Md., May 21 /PRNewswire-USNewswir... (ADAA),( http://www.adaa.org ) and The HealthCent... announced that ADAA will join,HealthCentral,s gro...and,health experts dedicated to helping people suf... advice and support they need to cope with the,con...
(Date:5/21/2008)...s 1st quarter profit, enhanced operations and new ...ELES, May 21 /PRNewswire-FirstCall/ -- InstaCare C...butor of at-home testing diagnostics,for the chron...eveloper of,patent-pending technologies for e-heal...s for the first quarter period-ended March 31, 200...
(Date:5/21/2008)... Adverse Events in TORCH Showed Frequency Highest ...ONTO and RESEARCH TRIANGLE PARK, N.C., May 21 /PRN...500/50 (fluticasone propionate and,salmeterol inha...er of,cardiovascular adverse events compared to ot...from the TOwards a Revolution in COPD Health,(TORC...
Breaking Medicine News(10 mins):Health News:Aflac Incorporated to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fourth Annual Strategic Decisions Conference 2008 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 2Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 4Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 5Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 2Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 3
...access to a high-profile detainee at Guantanamo Ba...n //techniques "national security secrets" whose r...e Washington Post reported Saturday.The US governm...must not be allowed to talk about the interrogatio...
...system to control HIV infection appears to depend ... molecules// called HLA Class I that have been inh...in those molecules display to the T lymphocytes th... the November issue of PLOS Medicine, researchers ...
...nts who behave in an unbecoming manner, and will n...an NHS hospital to punish patients// that disrupt .... The Royal Bolton hospital in Greater Mancheste...vernment to check violent behavior in hospitals. T...
...ng against time to prevent HIV, the virus that cau...the nation witnessing a rise in// the number of pr...s Public Health Division has launched a three-year...doms and voluntary testing of blood to prevent HIV...
Other Medicine News:Health News:Genes determine the capacity to fight HIV in early stages 2Health News:Genes determine the capacity to fight HIV in early stages 3Health News:HIV/AIDS Epidemic Scare In Bhutan 2
Malaria Pf. Assay Range
An immunochromatographic test for detection of 4 species of Plasmodium antigen ( P. falciparum , P. vivax , P. malariae , P. ovale ) in whole blood.
192 Test HRP-II Enzyme Immunoassay for the presence of Plasmodium falciparum infection.
Malaria device / strip (3 line, PAN-pLDH, P.f.-HRP2)
Medicine Products: